Wellbutrin XL Generic Needs Longer Study To Assess Switch Issues, Biovail Asserts
This article was originally published in The Pink Sheet Daily
Executive Summary
Bioequivalencey isn't the issue, Biovail says in response to proposed Teva study, arguing a much larger and differently designed trial should be conducted to investigate clinical differences between the generic and brand.
You may also be interested in...
Wellbutrin XL Generic From IntelGenx/Cary Pharma Delayed By Manufacturing, Food Effect Concerns
"Complete response" letter from FDA should be addressed by the end of the year, firms state.
Wellbutrin XL Generic From IntelGenx/Cary Pharma Delayed By Manufacturing, Food Effect Concerns
"Complete response" letter from FDA should be addressed by the end of the year, firms state.
FDA Aims To Bolster Generics' Image With Research, Regulatory Changes
FDA's Office of Generic Drugs is planning a multi-prong approach to boost public confidence in generic drugs, including scientific publications and possible changes in approval guidance, following a series of high-profile concerns raised about the quality of the products